(Q28444982)

English

TP53 Mutation

genetic variant

MUTATION

In more languages

Statements

Protein Altering Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

human chromosome 17

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

7571720

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

7590856

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

positive therapeutic predictor for

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/851

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

chronic lymphocytic leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1481

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

doxorubicin / etoposide / cisplatin combination therapy

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

stomach carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2820

Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/850

Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis

negative therapeutic predictor for

docetaxel trihydrate

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1146

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2784

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer

negative prognostic predictor for

head and neck squamous cell carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/518

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

esophagus squamous cell carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/519

p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus

myeloid neoplasm

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/522

Clinical significance of TP53 mutation in myeloma

head and neck squamous cell carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

statement disputed by

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/523

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck

head and neck squamous cell carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/524

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1018

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

adrenocortical carcinoma

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1028

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

chronic lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1450

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1478

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

chronic lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1451

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

chronic lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 5-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1452

TP53 mutation and survival in chronic lymphocytic leukemia

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1485

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

chronic lymphocytic leukemia

determination method

CIViC evidence level A

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1507

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

myelodysplastic syndrome

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/521

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

precursor B lymphoblastic lymphoma/leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/520

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

23 May 2022

https://civic.genome.wustl.edu/links/evidence/640

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/222

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444982&oldid=2014801331"